| Literature DB >> 23961495 |
Farida Chentli, Chentli Farida1, Faiza Belhimer, Belhimer Faiza.
Abstract
Gynecomastia is the most bothersome side effect in men taking antiandrogens. It is exceptionally severe and distressing physically and mentally as in the reported case. A man, aged 63, with a history of a well-treated macroprolactinoma, was referred in 2004 for gynecomastia that appeared after treatment by microsurgery, radiotherapy and flutamide for a lesion suspected to be prostate cancer. Clinical examination was normal except for huge enlargement of the breasts. Mammography and breasts MRI did not show any tumor. There was not any metastasis of the supposed prostate cancer and prostatic acid phosphates were within normal ranges. Hormonal exploration showed subclinical hypogonadism [testosterone: 7.4 ng/ml (n: 3-9), FSH: 14.9 mu/ml (n: 0.7-11) and LH: 9.7 mu/ml (n: 0.8-7.6)]. Testes ultrasounds were normal. Radiological and hormonal adrenal explorations were normal [Cortisol: 76 ng/ml (n: 50-250), DHEA-S: 59 μg/ml (n: 50-560), E2:40.2 pg/ml (n < 50)]. Body scan was normal too. The discussed etiologies were post radiation subclinical hypogonadism, and treatment with anti androgens. After flutamide withdraw, there was not any sign of prostate cancer recurrence, and gynecomastia decreased significantly, but did not disappear probably because of fibrosis.Entities:
Keywords: Aging; antiandrogens; gynecomastia; prostate cancer
Year: 2013 PMID: 23961495 PMCID: PMC3743379 DOI: 10.4103/2230-8210.113770
Source DB: PubMed Journal: Indian J Endocrinol Metab ISSN: 2230-9500
Figure 1(a) Clinical aspect of gynecomastia under flutamide, (b) After stopping flutamide: Increase in body hair, and decrease in breast size
Figure 2Chest X-ray like a woman's (a), mammography (b), and breasts MRI (c, d) showing dense bilateral glandular aspect
Hormonal assessment